Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 8/20 | 0.36 |
| ▸ | METAP1 | P53582 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 3/20 | 0.31 |
| ▸ | TDO2 | P48775 | 3/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163676 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL2163672 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL5954975 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL13134804 | 0.76 | BMP1 (0.38) | RENMETAP2METAP1 | |
| Trifluoroacetic Acid SCHEMBL5397425 | 0.68 | DPP7 (0.34) | — | |
| SCHEMBL3870308 | 0.65 | SMYD3 (0.36) | RAB9A | |
| SCHEMBL8291616 | 0.65 | SMYD3 (0.36) | RAB9A | |
| SCHEMBL3870311 | 0.65 | SMYD3 (0.36) | RAB9A | |
| SCHEMBL10177642 | 0.62 | POLB (0.46) | ALDH1A1RAB9A | |
| SCHEMBL7274162 | 0.62 | REN (0.55) | RENMETAP2METAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100239551-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-09-23 | — | — | US | disclosed |
| US-20100239551-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-09-23 | — | — | US | disclosed |
| WO-2008097673-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239551-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS8, PRSS1, PRSS2 | REN 972/4885METAP2 356/4885METAP1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.